34m
A drug already in human trials could reverse tooth loss by 2030, a condition that affects millions
Japanese biotech drug aims to reverse tooth loss by regrowing teeth. Here's how TRG-035 works, where trials stand and when it ...
These stocks have jumped in the double- and triple-digits.
Research rethinks amino acid origins, revealing insights into life’s earliest building blocks on Earth and potential clues ...
Complex chemical processes are essential for making DNA." This long-held assumption in the field of biotechnology has been overturned by a Korean ...
Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...
Investor's Business Daily on MSN
Why this biotech, up 12% since its breakout, yo-yoed on a key FDA development
Pharvaris stock jumped early Monday, but closed down, after the FDA agreed to review the company's treatment for a serious ...
(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...
Met a bulin, a Texas-based biotechnology company led by Hua Tu, PhD, is working to develop an ultra-stable insulin formulation that remains viable even at high temperatures. “Insulin instability has ...
Preview this article 1 min A Madrid, Spain-based cancer diagnostic firm seeks to grow its footprint to 21,000-square-foot at ...
The Vaccine Innovation Center at Korea University College of Medicine has been selected by the Korea Disease Control and ...
Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...
A series of biotech acquisitions transpired in under 9 months — totaling more than $3.5 billion. The drugs behind them target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results